New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
09:03 EDTITMNInterMune rises after Boehringer Ingelheim IPF trials hit primary endpoints
Boehringer Ingelheim’s INPULSIS-1 and -2 trials for nintedanib as a treatment for idiopathic pulmonary fibrosis, or IPF, showed that nintedanib 150 mg twice daily slowed disease progression by significantly reducing rate of decline in FVC and was associated with an acceptable side-effect profile, according to an abstract posted to the site of the American Thoracic Society. The Fly notes that InterMune is also developing a treatment for IPF. Shares of InterMune are up 8.7% to $35.71 in pre-market trading. Reference Link
News For ITMN From The Last 14 Days
Check below for free stories on ITMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
11:19 EDTITMNInterMune July weekly volatility elevated
Subscribe for More Information
July 17, 2014
12:42 EDTITMNInterMune receives FDA Breakthrough Therapy Designation for pirfenidone
InterMune announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. FDA. This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Pirfenidone is an investigational treatment for adult patients with idiopathic pulmonary fibrosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use